» Articles » PMID: 22673957

Tumor-induced Myeloid-derived Suppressor Cell Function is Independent of IFN-γ and IL-4Rα

Overview
Journal Eur J Immunol
Date 2012 Jun 8
PMID 22673957
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloid-derived suppressor cells (MDSCs) are present in most cancer patients and experimental animals where they exert a profound immune suppression and are a significant obstacle to immunotherapy. IFN-γ and IL-4 receptor alpha (IL-4Rα) have been implicated as essential molecules for MDSC development and immunosuppressive function. If IFN-γ and IL-4Rα are critical regulators of MDSCs, then they are potential targets for preventing MDSC accumulation or inhibiting MDSC function. Because data supporting a role for IFN-γ and IL-4Rα are not definitive, we have examined MDSCs induced in IFN-γ-deficient, IFN-γR-deficient, and IL-4Rα-deficient mice carrying three C57BL/6-derived (B16 melanoma, MC38 colon carcinoma, and 3LL lung adenocarcinoma), and three BALB/c-derived (4T1 and TS/A mammary carcinomas, and CT26 colon carcinoma) tumors. We report that although MDSCs express functional IFN-γR and IL-4Rα, and have the potential to signal through the STAT1 and STAT6 pathways, respectively, neither IFN-γ nor IL-4Rα impacts the phenotype, accumulation, or T-cell suppressive potency of MDSCs, although IFN-γ and IL-4Rα modestly alter MDSC-macrophage IL-10 crosstalk. Therefore, neither IFN-γ nor IL-4Rα is a key regulator of MDSCs and targeting these molecules is unlikely to significantly alter MDSC accumulation or function.

Citing Articles

A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells.

Welte T, Mai J, Zhang Z, Tian S, Zhang G, Xu Y iScience. 2021; 24(11):103349.

PMID: 34825135 PMC: 8603209. DOI: 10.1016/j.isci.2021.103349.


Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy.

Innamarato P, Pilon-Thomas S Cell Immunol. 2021; 361:104277.

PMID: 33476931 PMC: 7901256. DOI: 10.1016/j.cellimm.2020.104277.


Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression.

Yin K, Xia X, Rui K, Wang T, Wang S Front Oncol. 2021; 10:610104.

PMID: 33384962 PMC: 7770157. DOI: 10.3389/fonc.2020.610104.


The Gut Microbiota, Kynurenine Pathway, and Immune System Interaction in the Development of Brain Cancer.

Dehhaghi M, Kazemi Shariat Panahi H, Heng B, Guillemin G Front Cell Dev Biol. 2020; 8:562812.

PMID: 33330446 PMC: 7710763. DOI: 10.3389/fcell.2020.562812.


Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.

Law A, Valdes-Mora F, Gallego-Ortega D Cells. 2020; 9(3).

PMID: 32121014 PMC: 7140518. DOI: 10.3390/cells9030561.


References
1.
Pulaski B, Ostrand-Rosenberg S . Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998; 58(7):1486-93. View

2.
Chou H, Hsieh C, Yang H, Wang L, Arakawa Y, Brown K . Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology. 2011; 53(3):1007-19. PMC: 3079329. DOI: 10.1002/hep.24162. View

3.
Sinha P, Clements V, Ostrand-Rosenberg S . Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005; 174(2):636-45. DOI: 10.4049/jimmunol.174.2.636. View

4.
Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S . Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998; 92(11):4150-66. View

5.
Rabinovich G, Gabrilovich D, Sotomayor E . Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2006; 25:267-96. PMC: 2895922. DOI: 10.1146/annurev.immunol.25.022106.141609. View